Sapient
CRO & CDMO Services · Molecular Diagnostics
1open role
76H-1B filings in 12 months
Growinghiring pace, 56 of 100
38stories in the press
Overview
Discover dynamic biomarkers beyond the genome. Our multi-omics services enable profiling of thousands of metabolites, lipids & proteins per sample.
Key facts
As of Nov 13, 2026, Alion lists 1 open role at Sapient. Sapient is headquartered in San Diego, United States.
- Open roles
- 1Its careers board, read on Nov 13, 2026
- Headquarters
- San Diego, United StatesAlion company profile, updated Nov 13, 2026
- Visa sponsorship, United States
- 76 ▼ 13% · H-1B filings in 12 monthsUS Department of Labor · latest filing Jun 22, 2026
- Technologies in its job postings
- 6Named in its job postings
Funding and backers
Hiring now
1
+1 posted in 30 days
Momentum
28/100
hiring for its size, in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 22
Launched Sapient Launches GCLP-Compliant Workflows to Expand Support for Clinical Biomarker Testing · sapient.bio
Oct 2021
Website went live first capture in the Wayback Machine
Tractionpublic signals, read monthly
Web presence
top 8%
of 133.2M domains by links, Common Crawl
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
GenePlus is a Chinese precision medicine company that uses an AI-driven multi-omics platform for biomarker and target discovery…
Impact Proteomics is an immune profiling biotech company that leverages a unique and unbiased platform to enable antigen identification.
InterVenn is a biotechnology company that develops glycoproteomics technology to read a clinical layer of biology beyond the genome from a…
Our most in-depth DNA analysis. DNA Complete by Nebula Genomics analyzes 100% of your genome—unlike typical tests that read less than 1%…
Discover Omni 1000, the revolutionary proteomics platform offering 1000 high-fidelity proteins for cost-effective and rapid analysis in any…
MyOme is a clinical whole genome analysis platform company helping families understand their risk for inherited diseases. As a leader in…
Jobs
$100k – $160k per year · In office · Full-Time · San Diego
Mass Spectrometry
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$160k
Typical range
$160k
Open positions
1
1
Jobs
Senior
100%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 1 | $160k | $160k |
Highest paying role
Senior Research Scientist, Proteomics
$160k
Normalized to USD per year
Visa sponsorship
76 ▼ 13%
H-1B filings in 12 months
1
Green card filings
$153k
Median offered salary
Who they sponsor
Software developers
37
Other computer occupations
9
Data scientists
8
In the register as Sapient Corporation, Boston, MA (+1 more)
Other sponsors in the same field
Thermo Fisher Scientific 212 filings
Genscript 38 filings
Frontage Laboratories 27 filings
Curia 23 filings
See 1 open role Alert me
US Department of Labor · latest filing Jun 22, 2026 · Visa details by country
Growth
Hiring Momentum
56/100
Growing
Open positions
1
1 opened / 1 closed in 30 days
Median time-to-fill
126 days
faster than 9% of the market
ATS activity
Every ~6 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Marketing
33% ▼
Sales
33% ▼
Science & Research
33% ▲
Activity Timeline
Added Mass Spectrometry to stack
Oct 2026
Added Python to stack
Sep 2026
Added LinkedIn to stack
Sep 2026
Added HubSpot to stack
Sep 2026
Added Google Sheets to stack
Sep 2026
Added GitHub to stack
Sep 2026
Added Claude to stack
Sep 2026
Added ChatGPT to stack
Sep 2026
Added Microsoft Office to stack
Sep 2026
Tech stack
Technologies named in job postings at Sapient over the last 12 months, by layer, with the share of postings for each.
Technologies in use
6
Postings analysed
3
Stack modernity
88/100AI adopter
Languages
Python
Cloud & platforms
GCP
GitHub
AI & ML
ChatGPT
Claude
Practices & domains
Mass Spectrometry
Sign in to see how your skills match this stack
Sign In
News
Sapient Launches GCLP-Compliant Workflows to Expand Support for Clinical Biomarker Testing
These designated workflows meet enhanced quality and traceability standards required of assay data generated for clinical trials, including those supporting primary and secondary endpoints September 22, 2026 - San Diego, CA - Sapient, a leader in multi-om
Read more
Report
Vision Bank and Publicis Sapient announce strategic partnership to accelerate AI-powered banking innovation in Saudi Arabia
Partnership will establish an Innovation Hub and strengthen Vision Bank's product capabilities to accelerate the development of new services for customers
Read more
Report
An AI Foundation Model of Human Metabolic State
Patients who share the same diagnosis, driver mutation, or baseline lab value can respond to the same therapy in markedly different ways and progress along distinct trajectories. That heterogeneity is a primary driver of the industry's most expensive fail
Read more
Report
Sapient Contributes to Novel Findings Published in European Heart Journal Identifying Metabolite and Protein Signatures of Cardiotoxicity in Breast Cancer Patients
The multi-omics study, led by a prominent industry-academia collaborative, leveraged Sapient's discovery metabolomics platform to uncover new biomarkers of cancer therapy-related cardiac dysfunction and remodelling August 25, 2026 - San Diego, CA - Sapien
Read more
Report
Cardiac remodelling and dysfunction in cancer patients receiving cardiotoxic therapies: proteomic and metabolomic profiling
Sapient provided deep metabolomics profiling for this multi-omics study for cardiotoxicity biomarkers analysis - led by a large industry-academia collaborative and published in European Heart Journal - which uncovered new biomarkers of cancer therapy-rela
Read more
Report
Quantitative Protein Assays: Measuring the Proteins That Decide a Program
Drug programs increasingly succeed or fail based on a single measurement. Teams must be able to accurately measure proteins of interest: the target itself, a marker of mechanism, or a pharmacodynamic readout that shows the drug is working. For novel modal
Read more
Report
NULISAseq Immune 340 Panel
Sapient offers the NULISAseq Immune 340 Panel to capture the complexity of immune response biology in a single run - including regulatory proteins and low-abundance targets that standard platforms routinely miss.This panel spans innate and adaptive immuni
Read more
Report
A Protein Liquid Biopsy for Oncology
Liquid biopsy has changed how cancer is detected and monitored, yet its reach is still bounded by what circulating nucleic acids and rare cells can report. Circulating tumor DNA (ctDNA) sits at vanishingly low levels in early disease, clears quickly from
Read more
Report
FFPE as a Discovery Engine: Unlocking New Biology Hidden in the Archives
Every hospital pathology archive holds a resource that drug developers rarely think to mine for discovery: decades of formalin-fixed, paraffin-embedded (FFPE) tissue blocks collected from patients, each one linked to a diagnosis, a treatment course, and o
Read more
Report
What Your Tumor Biology Data Isn't Telling You: Closing the Functional Gap with Proteomics
Now On Demand Hosted by Technology Networks Every oncology R&D program eventually confronts the same key questions: Is our target of interest truly druggable in patient tumors? Are the relevant signaling pathways activated in the tumor and effectively mod
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
San Diego
San Diego
United States
HQ
In past, we have supported the communities around us viaphilanthropic events:
1 open roles 1 posted in 90 days 100% engineering $160k Avg Salary
hires for Science & Research
How to cite this page
Alion, "Sapient: key facts", as of Nov 13, 2026. https://alion.io/company/sapient-3
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0